Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...
Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.
Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL. The biggest news of 2023 for patients with lymphoma and provers ...
A population-based study from Sweden upends conventional thinking on when patients with mantle cell lymphoma (MCL) can exhale ...
Lymphoma represents a spectrum from indolent to aggressive disease; prognosis and management should be individualized by biologic behavior and owner goals. Avoid reflexively applying a single protocol ...
Blood Cancer UK, Lymphoma Action and stem cell charity Anthony Nolan have formally appealed against the decision.
Hosted on MSN
What Is Stage 3 Lymphoma?
Stage 3 lymphoma is a type of cancer that starts in a type of white blood cell called lymphocytes and has spread to lymph nodes on both sides of the diaphragm. It may also be in other organs near ...
What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease. It’s a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results